Corporate Governance Report
The Board of Directors and its Committees

The Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Mandate</th>
<th>Age</th>
<th>Independent 1)</th>
<th>First appointment</th>
<th>Expiration of current mandate 2)</th>
<th>Audit Committee member</th>
<th>Remunerations &amp; Nominations Committee member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joachim KREUZBURG</td>
<td>Chairman and Chief Executive Officer</td>
<td>54</td>
<td></td>
<td>2007</td>
<td>2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pascal BOISSEL</td>
<td>Director</td>
<td>53</td>
<td>•</td>
<td>2019</td>
<td>2022</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Amélie BUTON</td>
<td>Director representing employees</td>
<td>33</td>
<td></td>
<td>2019</td>
<td>2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan DEXTER</td>
<td>Director</td>
<td>64</td>
<td>•</td>
<td>2015</td>
<td>2021</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>René FÀBER</td>
<td>Director</td>
<td>44</td>
<td></td>
<td>2019</td>
<td>2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne-Marie GRAFFIN</td>
<td>Director</td>
<td>58</td>
<td>•</td>
<td>2015</td>
<td>2021</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Lothar KAPPICH</td>
<td>Director</td>
<td>62</td>
<td></td>
<td>2017</td>
<td>2022</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Henri RIEY</td>
<td>Director</td>
<td>58</td>
<td>*)</td>
<td>2007</td>
<td>2022</td>
<td>•</td>
<td>•</td>
</tr>
</tbody>
</table>

1) In accordance with the recommendation N°8 of the AFEP-MEDEF code
2) Directors are appointed until the date of the Annual General Shareholders’ Meeting called to approve the financial statement of the previous fiscal year ending.
3) In accordance with the criteria exposed within the recommendation N°8.5.6 of the AFEP-MEDEF code, Mr. Riey lost his independency qualification on June 29th, 2019, date of the twelfth anniversary of his first appointment as director of the company.
The company is administered by a Board of Directors composed of eight members, three of whom are independent. The directors are appointed for a three-year period.

The organization of the works of the Board and its composition must be suited to the shareholding structure, to the size and the nature of the activity of Sartorius Stedim Biotech S.A. and the particular circumstances it can face.

Composition of the Board of Directors as of 31 December 2019:

For historical reasons due to the shareholding structure of the Company, the composition of the Board of Directors and its Committees reflected the search by our reference shareholder of a long lasting balance between the Directors representing these shareholders, the Independent Directors and the executives.

Our reference shareholder takes its own responsibility towards the other shareholders, direct and distinct from the Board of Directors’ one. He takes particular care to avoid possible conflicts of interests in the transparency of the information provided to the market and to fairly take all interests into account.

The Board of Directors should consider what would be the desirable balance in its membership and that of the Committees it has established, in particular in the representation of women and men, nationalities and diversity of skills by taking measures appropriate to guarantee to the shareholders and to the market that its missions are carried out with the necessary independence and objectivity. It makes public in the Reference Document the objectives, methods and results of its politics on these subjects.

Joachim Kreuzburg
Chairman and Chief Executive Officer

Date of birth: 22 April 1965
Nationality: German

First appointment: 29 June 2007
Mandate renewed: 26 March 2019
Appointed until: date of the Annual General Shareholders’ Meeting in 2022 to approve the financial statements for the fiscal year ending 31 December 2021

Number of Sartorius Stedim Biotech Shares held: 6

Other current directorships and positions within the Group:

Chairman of the Executive Board (Vorstand) of Sartorius AG;
Chairman of the Supervisory Board of Sartorius Stedim Biotech GmbH;
Managing Director of Sartorius Lab Holding GmbH;
Managing Director of Sartorius Corporate Administration GmbH;
Managing Director of SWT Treuhand GmbH;
Managing Director of SI Weende-Verwaltungs-GmbH;
Managing Director of SI Grone 1-Verwaltungs-GmbH;
Managing Director of SI Grone 2 GmbH;
Managing Director of Sartorius Ventures GmbH;
Chairman of the Advisory Board of LabTwin GmbH;
Member of the Board of Directors of Essen Instruments, Inc.;
Chairman of the Board of Directors of Sartorius North America Inc.;
Member of the Board of Directors of Denver Instrument (Beijing) Co. Ltd.
Past directorships (held during the past five years) within the Group:

Vice Chairman of the Supervisory Board of Sartorius Stedim Biotech GmbH;
Managing Director of Sartorius Weighing Technology GmbH;
President of VL Finance S.A.S.;
President and Chairman of the Executive Committee of Sartorius Stedim FMT S.A.S;
Member of the Board of Directors of kSep Holdings, Inc.;
Member of the Board of Directors of ViroCyt, Inc.;
Chairman of the Board of Directors of Sartorius Stedim North America Inc.;
Member of the Board of Directors of IntelliCyt Corporation;
Chairman of the Board of Directors of Sartorius Stedim Filters Inc.;
Member of the Board of Directors of Sartorius Scientific Instruments (Beijing) Co. Ltd.;
Member of the Board of Directors of Sartorius Japan K.K.;
Member of the Board of Directors of Sartorius Stedim Japan K.K.;
Member of the Board of Directors of Sartorius Stedim Lab Ltd.;
Member of the Board of Directors of Sartorius Stedim BioOutsource Ltd.

Other current directorships and positions outside the Group:

Member of the Supervisory Board (Aufsichtsrat) of Carl Zeiss AG, Germany;
Vice Chairman of the Supervisory Board (Aufsichtsrat) of Ottobock SE & Co. KGaA, Germany;
Member of the Administrative Board (Verwaltungsrat) of Ottobock Management SE, Germany;
Member of the Economic Advisory Board (Wirtschaftsbeirat) of Norddeutsche Landesbank, Germany.

Past directorships (held during the past five years) outside the Group:

Chairman of the Advisory Board (Beirat) of Otto Bock Holding GmbH & Co. KG, Germany;
Member of the regional Advisory Board (Regionalbeirat) of Commerzbank AG, Germany.

Educational and professional background:

Diplom-Maschinenbau-Ingenieur, Dr. rer. pol. (University degree in mechanical engineering, doctorate in economics)


1995–1999 Research associate at the Faculty of Economics and Management at the University of Hanover, Germany

Since 1 May 1999 Sartorius AG, Goettingen, Germany

Most recent position before promotion to the Executive Board:
Vice President, Finances and Investor Relations

Since 11 Nov. 2002 Sartorius AG, Goettingen, Germany

1 May 2003, to 10 Nov. 2005 Spokesman (Sprecher) of the Executive Board of Sartorius AG, Goettingen, Germany

Since 11 Nov. 2005 CEO and Executive Board Chairman of Sartorius AG, Goettingen, Germany; currently responsible for Group Strategy, Human Resources, Corporate Research, Legal Affairs & Compliance, Communications
Lothar Kappich
Non-executive member
Date of birth: 15 February 1957
Nationality: German
First appointment: 14 September 2017
Mandate renewed: 26 March 2019
Appointed until: the 2022 Annual General Shareholders’ Meeting approving the financial statements for the fiscal year ending 31 December 2021
Number of Sartorius Stedim Biotech shares held: 1
Other current directorships and positions within the Group:
Chairman of the Supervisory Board of Sartorius AG.
Past directorships (held during the past five years) within the Group:
Member of the Supervisory Board of Sartorius AG.
Other current directorships and positions outside the Group:
None
Past directorships (held during the past five years) outside the Group:
Managing Director of ECE Projektmanagement GmbH & Co. KG, Germany.
Educational and professional background:
Doctorate (Dr. rer. pol.) in economics (subject of the doctoral dissertation: Theory of International Business Activity)
1988 - 1990 Controller in the Central Controlling Department from Schering AG in Berlin
1990 - 2017 ECE Projektmanagement G.m.b.H. & Co. KG in Hamburg, latest position Managing Director of ECE’s HR & Corporate Services as well as Managing Director of numerous subsidiaries at the ECE group
2007 - 2017 Member of the Supervisory Board of Sartorius AG, Goettingen
Since 2017 Chairman of the Supervisory Board of Sartorius AG, Goettingen

René Fáber
Non-executive member
Date of birth: 18 July 1975
Nationality: Slovak
First appointment: 26 March 2019
Appointed until: the 2022 Annual General Shareholders’ Meeting approving the financial statements for the fiscal year ending 31 December 2021
Number of Sartorius Stedim Biotech shares held: 1
Other current directorships and positions within the Group:
Member of the Executive Board of Sartorius AG;
Vice Chairman of the Supervisory Board of Sartorius Stedim Biotech GmbH;
Member of the Board of Directors of Sartorius Korea Biotech Co., Ltd.;
Member of the Board of Directors of Sartorius Stedim Japan K.K.;
Member of the Board of Directors of Sartorius Stedim (Shanghai) Trading Co., Ltd.;
President and Chairman of the Executive Committee of Sartorius Stedim FMT S.A.S.
Past directorships (held during the past five years) within the Group:
Managing Director of Sartorius Stedim Biotech GmbH;
Managing Director of Sartorius Stedim North America Holding GmbH.
Other current directorships and positions outside the Group:
None
Past directorships (held during the past five years) outside the Group:
Managing Director of Sartorius Stedim Biotech GmbH;
Managing Director of Sartorius Stedim North America Holding GmbH.
Educational and professional background:
Master degree in chemistry at the Technical University in Bratislava, Slovakia
PhD in polymer chemistry at the Technical University of Munich, Germany
2001 - 2002  Scientist at French specialty chemical group Rhodia, Slovakia
2002 - 2004  Post-doctoral researcher at Vivascience
2004 - 2018  Various positions at Sartorius Group (esp. Sartorius Stedim Biotech GmbH, Germany)
2004 - 2006  Scientist R&D Membrane Modification
2006 - 2010  Director development and production of surface modified membranes
2010 - 2013  Vice President R&D Process Technologies
2012 - 2014  Value Creation Agent in Supplier Relationship Center of Roche and Genentech, San Francisco, USA
2014 - 2017  Vice President Marketing and Product Management Filtration Technologies
2016 - 2018  Key Account Manager Roche/Genentech
2017 - 2018  Vice President Marketing and Product Management Fermentation Technologies
2018  Head of Product Development, Bioprocess Solutions Division
Since 2019  Head of Bioprocess Solutions Division of Sartorius Group, Member of the Executive Board of Sartorius AG, Germany

Henri Riey

Non-executive member
Date of birth: 5 November 1961
Nationality: Monegasque

First appointment: 29 June 2007
Mandate renewed: 26 March 2019
Appointed until: date of the Annual General Shareholders’ Meeting in 2022 to approve the financial statements for the fiscal year ending 31 December 2021

Number of Sartorius Stedim Biotech shares held: 6

Other current directorships and positions outside the Group:

President of Aidea;
President of Groupe HR S.A.S.;
Director and secretary-treasurer of The Princess Grace Foundation (Monaco)

Educational and professional background:

Diplôme Institut Supérieur de Gestion (France) (degree earned at the French Higher Institute of Business Management "Institut supérieur de gestion")

1985–1988  Fund Manager at Paribas bank
1988–1996  Fund Manager, responsible for the European Equity Fund Management Team at Barclays Bank, France
1996–1999  Head of Research of Barclays Asset Management Europe
1999–2004  Executive Vice President of Barclays Asset Management; in charge of all fund management businesses
2004 – 2013  CFO of Hendyplan S.A.
Anne-Marie Graffin

Non-executive member
Independent Director
Date of birth: 3 May 1961
Nationality: French

First appointment: 7 April 2015
Mandate renewed: 03 April 2018
Appointed until: date of the Annual General Shareholders’ Meeting in 2021 to approve the financial statements for the fiscal year ending 31 December 2020

Number of Sartorius Stedim Biotech shares held: 6

Other current directorships and positions outside the Group:

Member of the Supervisory Board of Valneva SE;
Member of the Supervisory Board of Nanobiotix S.A.;
Member of the Supervisory Board of M2Care S.A.S.;
Managing Director of SMAG Consulting SARL.

Past directorships (held during the past five years) outside the Group:

None

Educational and professional background:

Graduated from ESSEC (Ecole Supérieure des Sciences Economiques et Commerciales)

1984 - 1987 International Distillers and Vinters, France Products Manager
1988 - 1990 URGO Laboratories Marketing Manager
1991 - 1995 RoC S.A (Johnson & Johnson) - Head of International Marketing Group
1998 - 2000 Sanofi Pasteur MSD - France Products Manager Adults Vaccines
2001 - 2005 Sanofi Pasteur - Head of range then Europe Adults Vaccines Marketing Director
2006 - 2008 Sanofi Pasteur MSD - Executive Director Business Management
2009 - 2010 Sanofi Pasteur MSD - Vice President Business Management
Since 2011 Managing Director SMAG Consulting SARL - Advice Biotech and Medtech Strategy Management

Susan Dexter

Non-executive member
Independent Director
Date of birth: 11 October 1955
Nationality: American

First appointment: 7 April 2015
Mandate renewed: 03 April 2018
Appointed until: date of the Annual General Shareholders’ Meeting in 2021 to approve the financial statements for the fiscal year ending 31 December 2020

Number of Sartorius Stedim Biotech shares held: 6

Other current directorships and positions outside the Group:

None

Past directorships (held during the past five years) outside the Group:

Kalon Biotherapeutics, College Station, Texas, USA - CMO;
BioSense Technologies, Woburn, Massachusetts, USA - Clinical diagnostic technology based on cellular impedance.

Educational and professional background:

Degrees and Certifications: BS in Immunology and Marketing (double major, honors), American University, Washington, D.C., USA

Harvard University Negotiation Course for Lawyers, Harvard University, Cambridge, Massachusetts, USA

Finance for non-financial Managers, Harvard University through Dow Chemical Company internal training program

1975 - 1980 University of Massachusetts Medical School, Research, mammalian cell culture, animal toxicity studies, basic research
1980 - 1986 Collaborative Research, Biotechnology Sales in emerging markets for bioprocessing supplements and raw materials for biomanufacturing
1998 - 2004 Collaborative BioAlliance, Dow Chemical Company (Dow Biotechnology Contract
Pascale Boissel

Non-executive member
Indendent Director
Date of birth: 15 October 1966
Nationality: French

First appointment: 26 March 2019
Appointed until: the 2022 Annual General Shareholders’ Meeting approving the financial statements for the fiscal year ending 31 December 2021

Number of Sartorius Stedim Biotech shares held: 1

Other current directorships and positions outside the Group:

Member of the Board of Directors of Poxel S.A.

Past directorships (held during the past five years) outside the Group:

None

Educational and professional background:

Graduated from HEC (Ecole des hautes Etudes de Commerciales) : MBA in Finance & Audit

Graduated with a CPA diploma (diplôme d’expertise comptable & commissariat aux comptes)

2009 - 2012 IPSOGEN – Chief Financial Officer
2012 - 2016 BIOASTER Institute – Chief Financial Officer & Deputy Chief Executive Officer
2017 - 2018 ENYO PHARMA – Part time Chief Financial Officer
Since 2017 NOVADISCOVERY – Part time Chief Financial Officer
Amélie Buton

Non-executive member
Director representing the Employees
Date of birth: 20 April 1986
Nationality: French

First appointment: 26 September 2019
Appointed until: the 2022 Annual General Shareholders’ Meeting approving the financial statements for the fiscal year ending 31 December 2021

Number of Sartorius Stedim Biotech shares held: 1

Other current directorships and positions outside the Group:

None

Past directorships (held during the past five years) outside the Group:

None

Educational and professional background:

Graduated from Keele University (UK) - Law degree

Graduated from University Paris X - Master European and International Law

Graduated from University Paris V - Master International Business Law

2009 - 2010 L’Oréal – Legal Counsel (Asia/Africa/Middle East, Pacific Zone)
2010 – 2017 Voisin Consulting Life Sciences – Legal Counsel
Since 2017 Sartorius Stedim Biotech – Regional Counsel

Registered Addresses

With regards to their social mandates, the members of the Board of Directors and of the General Management are domiciled at the Company’s headquarters.

One Director representing employees since September 2019

One Director representing the employees is member of the Board of Directors. Ms Amélie Buton was appointed by the Work Council of the Company. She holds the duties of Regional Counsel. She was appointed in September 2019 for a 3-year term. Like any new Director, the Director representing the employees followed an induction course intended to perfect her knowledge of the Company’s organisation and activities, which involved in particular individual interviews with the Group’s main senior managers.

As soon as she took up her office, Ms. Amélie Buton has been participating, as secretary, to the meetings of the Audit Committee and the Remunerations and Nominations Committee.

Ms. Amélie Buton does not receive Directors’ fees as a Director representing the employees. The components of her remuneration as an employee are not published.

Independent Directors

The Company being controlled by a majority shareholder, the portion of independent administrator board members should be at least a third of the Board.

As of 31 December 2019, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of 43% of independent members under the independence criteria defined by the APEF-MEDEF code.

Pursuant to the principles of good corporate governance, the independent members may not be principal shareholders, employees, former Group employees, suppliers or bankers of the Group or major customers, nor may they have any other link likely to impair their judgment.

In accordance with the internal rules of the Board of Directors and in application of the AFEP-MEDEF code, the independence of directors is assessed each year with respect to the following criteria.

An independent director:

- May not be an employee or senior executive employee or director of his or her parent company or one of its consolidated companies and may not have been so during the five previous years (criterion 1);

- May not be a senior executive of a company in which the company directly or indirectly holds a director’s position or in which an employee as such or a senior executive of the company (either currently or having been so for less than five years) holds a director’s position (criterion 2);

- May not be a significant client, supplier, business banker or investment banker of the company or of its
group, for which the company or its group represents a significant part of its business (criterion 3);

- May not have any close family ties with one of the senior executives (criterion 4);

- May not have been a statutory auditor of the company for the five past years (criterion 5);

May not have been a director of the company for more than twelve years (criterion 6).

In addition to the abovementioned criteria, the Board of Directors analyses other factors, such as the ability to understand the issues and risks, prior to making a decision on whether a director qualifies as independent.

- As part of the Assessment of the Board of Directors, the Board of Directors goes through all the criteria listed above and currently it states that it has three independent directors: Mrs. Pascale Boissel, Mrs. Susan Dexter, Mrs Anne-Marie Graffin.

<table>
<thead>
<tr>
<th>Name</th>
<th>Not an employee or executive officer</th>
<th>No cross-directorships</th>
<th>No significant business relationships</th>
<th>No family links</th>
<th>Not a statutory auditor</th>
<th>First appointment</th>
<th>Not a director for over 12 years</th>
<th>Classification adopted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joachim Kreuzburg</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2007</td>
<td>Yes</td>
<td>Not independent</td>
</tr>
<tr>
<td>Pascale Boissel</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2019</td>
<td>Yes</td>
<td>Independent</td>
</tr>
<tr>
<td>Henri Riey</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2007</td>
<td>No</td>
<td>Not Independent</td>
</tr>
<tr>
<td>René Fäber</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2019</td>
<td>Yes</td>
<td>Not Independent</td>
</tr>
<tr>
<td>Susan Dexter</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2015</td>
<td>Yes</td>
<td>Independent</td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2017</td>
<td>Yes</td>
<td>Not independent</td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2019</td>
<td>Yes</td>
<td>Not independent</td>
</tr>
<tr>
<td>Amélie Buton</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) Particular attention was paid to the situation of Mrs. Susan Dexter, who holds a position at Latham Biopharm Group Inc., a company with whom Sartorius Stedim Biotech GmbH signed a consultancy agreement, which expired on December 31, 2017 and has not been renewed. The Board noted that the relation between these two companies were not significant in terms of their volume. In addition, the possibility for Sartorius to use a panel of providers having similar expertise than Latham Biopharm Group, in a competitive context, rules out all relationship of dependence.

2) Mr Henri Riey first mandate as director of the company occured on June 29th, 2007. As a consequence, the criteria N°6 of the recommandation N°8 of the AFEP MEDEF code (not being a director of the company for more than twelve years) is not fulfilled anymore since June 29, 2019. Therefore, Mr Henri Riey correlatively lost his quality of independent director as of that date.

Balanced representation of women and men

Each year, the Board of Directors examines the desired balance in its composition and that of its committees, seeking in particular a balanced representation of men and women, and a wide diversity of skills and nationalities, reflecting as best it can both the highly technical and global nature of the company’s business.

Specifically, as regards the threshold of 40% women to be reached under the provisions of Article L. 225 - 18 - 1 of the French Commercial Code, the Board of Directors has put significant effort into searching for skilled, independent and dedicated female directors with a proven level of expertise in biotechnologies or related industries. As of 31 December 2019, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of 43% of women.

Assessment of the Board of Directors

The internal rules of the Board of Directors require that once a year the Board devotes an item on its agenda to discuss its functioning and ensures that a formal assessment is carried out. For this purpose, in December 2019, members of the Board completed a questionnaire on the following topics:

- the Board’s composition;
- the mode and structure of governance;
- the effectiveness of the Board of Directors;
- the Board’s working methods;
- the areas of competence of the Board’s members;
- areas for improvement.

Consistent with last year’s efficiency review, the results are satisfactory in terms of flow of information,
active participation of each Board members, quality of the Committee’s work. Those answers are reflecting the high quality teamwork of Board members and their convergence of views.

**Board of Directors’ internal rules**

The Board of Directors has adopted a set of internal rules that defines and includes rules of operation for this body relating to its powers, members’ attendance, operations requiring approval and prior validation with a certain number of triggering thresholds. The directors’ charter is included in the Annex and defines the rights and obligations of directors, in particular regarding the code of ethics and prevention of conflicts of interest. The Board of Directors updated their internal rules during the meeting that took place on February 2019, with the purpose of ensuring compliance with the latest legal, regulatory and statutory obligations applicable to the Company, as well as the last update of the AFEP-MEDEF governance code of June 2018.

**Staggering of the mandate terms**

According to the APEF MEDEF governance code for listed companies, the staggering of terms should be organized in order to avoid renewing a group of mandates and to promote harmonious renewing of the directors’ mandates. The afferent rule relating to staggering terms is respected, as such, on December 31, 2019 five expiring memberships were considered, among of which three were renewed (M. Kreuzburg, M. Kappich and M. Riey), and two were subject to new nominations (Ms. Boissel and M. Fáber, as a replacement of Ms de Lassus and M. Lemaitre, whose mandates expired).

**Plurality of mandates**

In accordance with the APEF MEDEF governance code for listed companies, an executive Director can’t exercise more than two other mandates of Director in listed companies outside its group, including foreign companies. It should in addition collect the notice from the Board before accepting a new Director mandate in a listed company.

Moreover, an administrator can’t exercise more than four other mandates in listed companies outside its group, including foreign companies. This recommendation is applied during the nomination or the renewal of the administrator’s mandate.

Procedures established and followed by the Committees are set up within their respective internal regulations.

Committee’s members are appointed by the Board of Directors. A special attention is paid by the Board of Directors to the nomination of renewal of the mandate of the Chairman of the Audit Committee, upon recommendation of the Remunerations and Nominations Committee.
Other Information

The Board of Directors met eight times during fiscal 2019.

The preparation and holding of the meetings of the Board of Directors and its Committees require significant availability and investment by the Directors. In 2019, the attendance rate at Board meetings was 97% on average. The individual attendance rate at Board and Committee meetings is specified below.

The allocation of Directors’ fees, based on the rate of attendance by each of the Directors at Board meetings and presence at the meetings of its various Committees, is described in page 89 of the present Universal registration Document.

<table>
<thead>
<tr>
<th>Name</th>
<th>Board of Directors</th>
<th>Audit Committee</th>
<th>Remunerations and Nominations Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joachim Kreuzburg</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pascale Boissel</td>
<td>100%</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>(from March 26, 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amélie Buton</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(from September 26, 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Dexter</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>René Faber</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(from March 26, 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td>100%</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Henri Riey</td>
<td>75%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Liliane de Lassus</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>(until March 26, 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bernard Lemaitre</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>(until March 26, 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AVERAGE 2019</strong></td>
<td><strong>97%</strong></td>
<td><strong>100%</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

To the company’s knowledge, within the last five years, no member of the Board of Directors:

- has been convicted of fraud during the last five years or has been subject to any official public investigation or sanction by statutory regulatory authorities;
- has been associated in his/her capacity of manager in any bankruptcy, receivership or liquidation for the past five years;
- has been disqualified by a court from acting in the capacity of a member of an administrative, management or supervisory body of an issuer or from acting in the capacity of a management executive or conducting the business of any issuer for the past five years.

To the company’s knowledge, no family relationships exist among the members of the company’s Board of Directors.

Furthermore, to the company’s knowledge, there is no conflict of interest between any duty of the members of the Board of Directors and their private interests and/or other duties. A Director must inform the Board as soon as he/she is aware of any conflict of interests, or even the possibility of a potential conflict, and must refrain from any participation in discussions on the relevant subject matter and from voting on any associated resolutions.

To the company’s knowledge, no settlement or agreement has been reached with shareholders, clients, suppliers or others to appoint a member of the Board of Directors.

In accordance with the bylaws of Sartorius Stedim Biotech S.A. Company, each Director owns personally at least one share of the company.

All Directors fulfill the below mentioned thresholds with regards to numbers of mandates in listed companies:

- For the executive Directors: maximum of two mandates in companies not belonging to the group,
- For non-executive Directors: maximum of four mandated in companies not belonging to the group.
To the company’s knowledge, there is no service contract linking a Board member to the Sartorius Stedim Biotech Group and granting him or her benefits.

Measures taken to ensure that control is not done in an abusive way are the following:

- Three members of the Board of Directors out of seven are Independent Directors.
- Two independent members of the Board out of three are members of the Audit Committee, one of them being the Chairwoman of such committee.
- Two independent members of the Board out of three are members of the Remunerations and Nominations Committee.

Conditions for Preparation and Organization of the Work of the Board of Directors

**Internal Rules and Regulations**

The procedures governing the organization and functioning of the Board of Directors are defined by the Internal Rules and Regulations of the Board which is published on the website of Sartorius Stedim Biotech S.A. as of the publication of this particular report.

The Internal Rules and Regulations currently applicable has been adopted on 7 February 2019 with the purpose of ensuring compliance with the latest legal, regulatory and statutory obligations applicable to the Company, as well as the last update of the AFEP-MEDEF governance code of June 2018.

The Board of Directors deals with all matters concerning the proper operation of the company and takes decisions on subjects that concern it.

**Its Missions**

The main missions of the Board of Directors are as follows:

- The Board of Directors shall define the company’s strategic goals and assess them from an overall perspective at least once a year, as proposed by the CEO, and ensure that these goals are implemented. It shall also appoint the corporate officers responsible for managing the company in pursuit of this strategy and review all delegations of authority;
- The Board of Directors shall review the management of the Group and monitor the quality of information provided to shareholders and to the market through the financial statements or when material events occur, especially about the company’s shareholdings;
- The Board of Directors is responsible for approving all strategic investment projects and any transaction, in particular acquisitions or disposals, likely to materially affect the company’s results, the structure of its balance sheet or risk profile;
- The Board of Directors will beforehand decide for each significant transaction outside the scope of the announced strategy;
- The Board of Directors shall deliberate prior to making any changes to the management structure of the company, and shall be informed of the principal organizational changes;
- The Board of Directors shall examine the corporate and consolidated accounts and approve the management report and the sections of the annual report dealing with corporate governance and those setting out the company’s policies with respect to remuneration and stock options;
- Although it is not a modification with a social purpose, the Board of Directors must seize the Shareholders’ Meeting if the transaction concerns a preponderant share of the assets or the activities of the group;
- The Board of Directors shall convene annual shareholders’ meetings and propose changes to the articles of association.

The missions mentioned above summarize the internal bylaws of the Board of Directors.
Activity Report of the Board of Directors for Fiscal 2019

The Board reviewed and approved the corporate and consolidated accounts for 2018.

The Board of Directors considered and debated on the following at its meetings:

– Strategic direction and major Group projects.
– The annual, half-year and quarterly financial statements.
– Budgets presented by executive management.
– Information on the financial structure and cash flow items.
– Significant off-balance sheet commitments.
– Risk indicators for the Group.
– Stock market performance.
– Self-assessment of the Board members.
– Elements of remuneration due or attributed.
– Appointment of a Director representing the employees
– Renewal of the mandates of members of the Board of Directors
– Approval of several acquisitions projects

Information to be Provided to Directors

Before each Board Meeting, Directors receive a report on the agenda items that require prior consideration, in due time and following notification.

Preliminary figures of the annual and interim statements are generally sent to all Directors at least one week before the meeting of the Audit Committee, which is always held on the day of or on the day before the Board meeting.

In addition to Board meetings, the Chairman regularly informs the Directors of any event or development that may have a material impact on Group operations or on any information previously communicated to the Board.

The members of the Board of Directors receive a copy of each press release published by the Company. The Directors may, at any time, request further information from the Chairman of the Board, who shall assess the relevance of the request.

The Audit Committee and the Remuneration and Nominations Committee are responsible for studying and making preparations for the Board’s main deliberations in order to improve the Board’s efficiency.

Under no circumstances do these Committees relieve the Board which has the only legal power of decision nor are allowed to cause division within its college which is and stays responsible of the accomplishment of its missions. The Committees don’t replace but are an emanation of the Board of Directors facilitating its work.

The Committees of the Board may consult, in the performance of their functions, any of the main company’s executive members after having informed the Chairman of the Board of Directors and subject to reporting back to the Board.

The Committees of the Board may request external technical studies relating to matters within their competence, at the expense of the Company, after having informed the Chairman of the Board of Directors or the Board of Directors itself and subject to reporting back to the Board.

In the event the Committees solicit the services of external counsels (e.g. the Remuneration Committee for the purpose of gathering information related to systems and levels of remunerations applicable within the main markets), the Committees shall ensure the objectiveness of the sought advice.

Each Board of Directors meeting is preceded with at least one meeting of one of the two committees, depending on the addressed topics. The Committees remain accountable to the Board of Directors and address to them their position, advice and recommendations.

Procedures established and followed by the Committees are set up within their respective internal regulations.

Committees’ members are appointed by the Board of Directors. A special attention is paid by the Board of Directors to the nomination of renewal of the mandate of the Chairman of the Audit Committee.
The Audit Committee

The Audit Committee assists the Board of Directors in areas relating to accounting policy, reporting, internal and external control, financial communication and management of the risks to which the company is exposed.

Audit Committee duties

Regarding accounting policy and internal control, the Audit Committee has the following duties:

– To proceed as soon as possible, and in any event prior to examination of the annual parent company financial statements and, where appropriate, the consolidated financial statements by the Board of Directors, with the review of all the financial, interim and annual parent company and, where appropriate, consolidated financial statements, including their notes and, where appropriate, the management report presented by the Board of Directors to the General Meeting of Shareholders called to approve the financial statements for the year ended and to present its observations to the Board of Directors. During the examination of the financial statements, the Committee pays particular attention to significant transactions that could have given rise to a conflict of interests;

– To ensure the pertinence of the selected methods and accounting procedures chosen by the company and to check their proper application;

– To check the accounting treatment of any significant transaction made by the company;

– To ensure that the internal procedures for data collection and control are sufficient to ensure the quality and reliability of the annual parent company financial statements and, where appropriate, the company’s consolidated financial statements;

– To examine the scope of the consolidated companies and, where appropriate, the reasons for which any companies are not included.

Regarding external control, the Audit Committee has the following duties:

– To submit to the Board of Directors recommendations concerning the Statutory Auditors in view of their appointment or renewal by the General Meeting of Shareholders, to analyse and issue an opinion on the definition, extent and timetable of their assignment and their fees. For this purpose, the Committee steers the selection procedure for the Statutory Auditors and submits to the Board of Directors a recommendation on the Statutory Auditors proposed for appointment by the General Meeting of Shareholders. The Committee proposes to the Board the selection procedure and, in particular, whether a call for tender should be issued. It supervises the call for tender and approves the specifications and the selection of the companies consulted, taking care to select the "best bid" and not the "lowest bid";

– To ensure the independence of the Statutory Auditors.

Regarding risk analysis and prevention, the Audit Committee has the following duties:

– To analyse all disputes, including fiscal, that may have a significant impact on the parent company financial statements and, where appropriate, the company’s consolidated financial statements, or its financial position;

– To examine the company’s exposure to significant financial risks. The Committee examines the risks and significant off-balance sheet commitments and assesses the importance of malfunctions or weaknesses that it is made aware of and informs the Board, as appropriate;

– To review the conclusions of internal audit reports;

– To verify the satisfactory application of internal controls and information reporting procedures.

Regarding financial communication, the Audit Committee’s duties include reviewing the company’s financial communication projects relating to the annual and interim parent company financial statements, as well as quarterly sales.

Given the extent of its remit, the Audit Committee consults with the Statutory Auditors, but also with the Finance, Accounts and Treasury Directors. These meetings may be held, at the Committee’s request, without the Company’s executive bodies being present.
Composition of the Audit Committee

The Audit Committee comprises at least three members chosen by the Board of Directors for their accounting and finance expertise, of whom one must be an independent member.

The independence criteria retained by the Audit Committee’s internal rules are based on those proposed by the recommendations of the AFEP MEDEF code and the Ethics code and adapted to suit the company’s size, organization and means.

Audit Committee’s internal rules

The Audit Committee has adopted a set of internal rules and a charter designed to provide a framework for its duties and operation and, in particular, to ensure the implementation and application of independence criteria for its members. It also includes the conditions for remuneration of the latter.

As of 31 December 2019, the Audit Committee has four members:

- Mrs. Pascale Boissel,
  Chairwoman of the Committee since March 26, 2019
- Mrs. Anne-Marie Graffin
- Mr. Lothar Kappich
- Mr. Henri Riey

The Chairwoman of the Audit Committee is independent.

The Chairman of the Board of Directors, who is also the CEO of the Group, is a permanent guest of the Audit Committee, but has no voting rights.

The Director representing the employees is also a guest of the Audit Committee and act as the secretary of the meetings.

The Audit Committee met five times during fiscal 2019.

Remunerations and Nominations Committee

Remunerations and Nominations Committee duties

The Remuneration and Nominations Committee’s purpose is to assist the company’s Board of Directors in setting the remuneration policy for corporate officers and, in particular, relating to incentive mechanisms (allocation of stock options and bonus shares) that the company may implement.

During the year, the Remuneration and Nominations Committee may consult all the company’s executive members, after it has informed the Chairman of the Board of Directors, and must report on this to the Board.

The Remuneration and Nominations Committee’s duties also include assisting the Board of Directors with the appointment of new Board members.

Composition of the Remuneration and Nominations Committee and functioning

As of 31 December 2019, the Remuneration and Nominations Committee has four members:

Mr. Lothar Kappich, appointed member of the Remuneration of Nominations Committee during the Board of Directors meeting that took place on October 10, 2017, was appointed Chairman of the Committee by its members during the meeting held on 15 February 2018. His mandate as Chairman of the Committee was renewed on March 26, 2019.

- Mrs. Anne-Marie Graffin
- Mrs. Susan Dexter
- Mr. Henri Riey

Two of the four members of the Remuneration and Nominations Committee are independent.

The Remuneration and Nominations Committee met once in fiscal 2019.
Report on Corporate Governance

1. Regulated Agreement

Continued agreement

The Company has decided to continue the services agreement between the Company and Sartorius AG, made effective retroactively since January 1st, 2015 and adopted by the Annual Shareholders meeting of April 4th, 2017, and covering the recharge of services of the Company’s Officers.

Consequently, and in accordance with the provisions set out in Article L. 225 - 40 - 1 of the French Code of Commerce, the Company will propose to its Board of Directors of February 6th, 2020 and further to its Annual Shareholders meeting of March 24th, 2020 to approve the continuation of the said agreement (as below detailed).

The said agreement contains the following modalities:

Nature: General assistance and administrative services

Purpose: formalization of the recharges between the Company and its parent company.

Amounts:

For Mr. Joachim Kreuzburg:
Year 2018: 674,216€
Year 2019: 582,804 €

For René Fäber:
Year 2019: 410,004€

This regulated agreement has been rejected by the Shareholders during the Annual Shareholders Meeting of March 26th, 2019.

New agreement as of 31 December 2019

The Company has decided to sign a new amendment to the services agreement between the Company and Sartorius AG, made effective retroactively since January 1st, 2015 and adopted by the Annual Shareholders meeting of April 4th, 2017, and covering the recharge of services of René Fäber.

The said agreement contains the following modalities:

Nature: General assistance and administrative services

Purpose: formalization of the recharges between the Company and its parent company.

Amounts:

For René Fäber:
Year 2019: 410,004€

Consequently, and in accordance with the provisions set out in Article L. 225 - 40 - 1 of the French Code of Commerce, the Company will propose to its Board of Directors of February 6th, 2020 and further to its Annual Shareholders meeting of March 24th, 2020 to approve the said amendment.

2. Regulated commitments concerning Mr. Joachim Kreuzburg

There are certain commitments described in this section that are regarded as regulated under French Regulation.

Such commitments were subscribed by Sartorius AG in accordance with the global remuneration policy of the Group; 20% of their total amounts are re-charged to the Company.

These commitments were rejected by the Annual Shareholders meetings of March 26th, 2019 and April 3rd, 2018. They were nonetheless approved by the Board of Directors on February 7th, 2019. They will be submitted to the approval of the Annual Shareholders meeting called on March 24th, 2020 to approve the financial statements for the fiscal year ending 31 December 2019.

These commitments subscribed by the German parent company comply with the German law.
Earlier departure severance

The service contract of Joachim Kreuzburg includes a severance pay cap of a maximum of two annual salaries to cover cases in which Sartorius AG Executive Board membership is terminated prematurely.

Non-competition clause

Joachim Kreuzburg has a post-contractual non-competition obligation, which is in accordance with German law. This obligation will last for two years after an Executive Board member has left the Group. During this time, if the non-competition clause is not waived or terminated, this Executive Board member may claim half of his most recent annual remuneration received from the company.

Pension commitments

Mr. Joachim Kreuzburg benefit from a supplementary pension scheme that is applicable under German Law. These commitments and their modalities are exhaustively described in the section Remuneration Report of this annual report.
Since fiscal 2008, the Sartorius Stedim Biotech S.A. Board of Directors decided to follow the AFEP-Medef recommendations, as revised in June 2018, as the reference code for corporate governance (see www.medef.fr).

The AFEP-Medef Corporate Governance Code (the “Code”) defines a set of regulations for good and responsible corporate governance. It follows the “comply or explain” principle that is implemented in most countries of the European Union. If a listed company does not comply with a recommendation of this Code, it must explain this in its corporate governance report.

In accordance with article 27.1 of the Corporate Governance Code for listed companies in effect from the presented date (the “Code”); listed companies referring to the code are required to precisely identify, in their Universal Registration Document, the application of these recommendations. In case of non-application of one of these provisions, companies are required to provide a comprehensible, relevant and circumstantial explanation according to the rule “apply or explain”. It is recommended by the AMF (recommendation n°2014-08 of 22 September 2014) that companies indicate in a specific table each recommendation that are not applied and the related explanations.
SPECIFIC TABLE ON RECOMMENDATIONS OF THE AFEP MEDEF CODE FOR THE GOVERNANCE OF LISTED COMPANIES

<table>
<thead>
<tr>
<th>ARTICLE</th>
<th>DEVIATIONS OF THE PROVISIONS OF THE CODE</th>
<th>EXPLANATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2</td>
<td>Disclosure of the option selected</td>
<td>The Board of Directors has opted for the Chairman’s functions meeting of the Board Committee and as Chief Executive Officer in order to simplify the company operational management and increase its effectiveness.</td>
</tr>
<tr>
<td></td>
<td>It is essential for the shareholders and third parties to be fully informed of the choice made between separation of the offices of Chairman and Chief Executive Officer and maintenance of these positions as a single office.</td>
<td>This organization turned out to be a factor of efficient governance considering the organization of the Sartorius Stedim Biotech Group. Mr. Joachim Kreuzburg is Chairman of the Board and CEO of Sartorius AG mother company of the group. He is on one hand bound to the controlling shareholder and on the other hand very involved in the business affairs of the Group which he particularly knows and experienced. Also, the Board of Directors is proceeding to an annual evaluation of its functioning to identify the improvements that could be made. The result of the evaluation shows that this organization is well suited for the interests of the company.</td>
</tr>
<tr>
<td>10.3</td>
<td>Non-executive directors meeting</td>
<td>Board meetings are organized in the presence of the executive members to maintain the same degree of information between the members of the Board and strengthen the open and transparent collective character. According to the Code AFEP-MEDEF planning that the non-executive members have to meet annually without the presence of the executive or internal members, the internal rules of the Board mentions the possibility for the non-executive members to organize this kind of meeting. The concerned Directors have duly been made aware of this possibility but did not express their wish to hold such a meeting during the past year. They will be reminded of such a possibility during the first Board of Directors Meeting that will occur for the next financial year.</td>
</tr>
<tr>
<td></td>
<td>It is recommended that the non-executive directors meet periodically without the executive or ‘in-house’ directors. The internal rules of operation of the Board of Directors must provide for such a meeting once a year, at which time the evaluation of the Chairman’s, Chief Executive Officer’s and Deputy Chief Executive’s respective performance shall be carried out, and the participants shall reflect on the future of the company’s executive management.</td>
<td></td>
</tr>
<tr>
<td>15.1</td>
<td>Independent directors within the Audit Committee</td>
<td>On December 31, 2019, 50% of the Audit Committee members are independent (i.e. two members out of four). This is the direct consequence of the loss of the status of independent of one of its member during the fiscal year ended on December 31, 2019 (Mr. Henri Rey). The Audit Committee is chaired by an independent administrator: Mrs. Pascale Boi. In view of the high experience in finance topics of the members of the Audit Committee, and in particular of its chairwoman, the Board of Directors considers that the current composition ensures the efficiency of the work of the Committee. No executive director is sitting within the Audit Committee.</td>
</tr>
<tr>
<td></td>
<td>The proportion of independent directors on the audit committee (excluding the directors representing employee shareholders and directors representing employees, who are not taken into account) should be at least equal to two-thirds, and the committee should not include any executive director.</td>
<td>For practical reasons, connected in particular to the presence within the Committee of a majority of nonresident members, the meetings of the Audit committee usually take place the same days as those of the Board of Directors. Taking into consideration this obligation, and in order to give to the Audit committee the possibility of achieving completely its missions, the internal rules of the Board mentions that any documents and useful information must be communicated to the Board by the Chairman and Chief Executive Officer upfront and in a sufficient delay. The files are like this transmitted to the members of the Audit Committee with a sufficient upstream delay and at the latest three days before every meeting of the Committee or of the Board allowing them to have a sufficient delay for the examination of the statements before these meetings. Therefore, each member of the said committee is spending the necessary time to examine each topic and is duly enabled to require such information if needed.</td>
</tr>
<tr>
<td>15.3</td>
<td>Examination deadline of the accounts between the Audit Committee and the Board</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The appointment or extension of the term of office of the audit committee’s Chairman is proposed by the appointments/nominations committee, and should be specially reviewed by the Board.</td>
<td></td>
</tr>
<tr>
<td>ARTICLE</td>
<td>DEVIATIONS OF THE PROVISIONS OF THE CODE</td>
<td>EXPLANATIONS</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>16/17</td>
<td>THE COMMITTEE IN CHARGE OF REMUNERATIONS AND NOMINATIONS</td>
<td>The Board of Directors decided to create a Remunerations and Nominations Committee.</td>
</tr>
<tr>
<td>16.1/17.1</td>
<td>Independent directors within the Remunerations and Nominations Committee: It must mostly consist of independent directors. It is recommended that the Chairman of the committee should be independent.</td>
<td>On December 31, 2019, 50% of the Remunerations and Nominations Committee members are independent (i.e. 2 members out of four). This is the direct consequence of the loss of the status of independent of one of its member during the fiscal year ended on December 31, 2019 (Mr. Henri Riey). It is further mentioned that the Chairman and Chief Executive Officer of the Board is not a member of the committee. For historical reasons related to the company share options, the composition of the specialized committee was reflecting the research by our shareholder in order to reflect a balance between the directors representing the shareholders and the independent directors. Lothar Kappich has been appointed Chairman of the Remunerations and Nominations Committee of the Sartorius Stedim Biotech Group for management and coherency reasons: Although Mr. Lothar Kappich is non-independent, he is also the Chairman of the remunerations committee of the Sartorius Group AG. It is recommended that one of its members should be an employee director. The director representing the employees, without being a member of the Remunerations and Nominations Committee, has been appointed by the Board of Director to attend the meetings as secretary. Discussions related to remunerations and advantages of Company's officers are therefore fully transparent and shared with the Director representing the employee.</td>
</tr>
<tr>
<td>19.</td>
<td>ETHICAL RULES FOR DIRECTORS</td>
<td>The Board of Directors has implemented these ethic principles within its internal regulations, in particular within the Director Charter, which is attached to the internal regulations. Beyond the application of Article L 225 - 25 of the French Code of Commerce, the Board of Directors has left until now the freedom to each director to invest significantly or not within the company.</td>
</tr>
<tr>
<td>21.</td>
<td>TERMINATION OF EMPLOYMENT CONTRACT IN THE EVENT OF BECOMING A COMPANY OFFICER</td>
<td>This recommendation is not applied since there are no Company's officer under an employment contract within the company. According to German law, it is not necessary to change such an employment contract when a person becomes a Managing Director of the company he/she works for. It should also be considered that the Sartorius Stedim Biotech Group is controlled by a German majority shareholder, and the biggest group company is a German company; therefore, in this respect German rules and regulations are very common in the whole group and have to be observed at the respective group level.</td>
</tr>
<tr>
<td>21.1</td>
<td>When an employee is appointed as a company officer, it is recommended to terminate his or her employment contract with the company or with a company affiliated to the group, whether through contractual termination or resignation.</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>24.3.2</td>
<td>Annual variable compensation of executive officers. The rules for fixing this compensation must be consistent with the annual review of the performances of the executive officers and the corporate strategy. They depend on the director's performance and the progress made by the company.</td>
<td></td>
</tr>
</tbody>
</table>

Mr Joachim Kreuzburg is representing the Group Sartorius AG, his compensation policy is deliberated and decided at the level of the headquarter Sartorius AG. The performance action elements are detailed in the document reference within the parts of the corporate governance Report and the internal control within this Registration Document. It is also reminded that this variable compensation is exclusively allocated by Sartorius AG, and, as such, performance rules are decided under the German legislation, through applicable governance codes.

Company officers who are beneficiaries of stock options and/or performance shares must make a formal commitment not to engage in any hedging transactions in respect of their own risks with regard to options, shares resulting from the exercise of options or performance shares, and to respect this commitment until the end of the share retention period determined by the Board of Directors.

SSB's Company officer received its remuneration directly from Sartorius A.G., major shareholder of Sartorius Stedim Biotech. To such extent, no company officer of Sartorius Stedim Biotech is a beneficiary of stock options and/or performance shares, hence the absence of such commitment.

24.5.1  | Departure of company officers. It is not acceptable that directors whose company has failed or who have personally failed may receive benefits upon departure. |

Severance payments for Joachim Kreuzburg are defined in the course of the remuneration program at the headquarter level Sartorius AG, and are capped. Further and detailed information related to these severance payments are available within the report on the remuneration of the Executive Director inserted in this Universal Registration Document.
Convening

Annual (or Ordinary) General Shareholders’ Meetings are those convened to take all decisions that do not result in a revision of the bylaws. Extraordinary General Shareholders’ Meetings are those called to decide or authorize direct or indirect revisions to the bylaws. Special Meetings bring together the holders of a specific class of share to consider revisions to the rights of this class of share. Decisions made at the General Meetings are binding for all shareholders, even those who are absent, dissenting or legally incapable or incapacitated. General Meetings are convened by the Board of Directors or, by default, the independent auditors or a person thus empowered. General Meetings are held at the registered office or any other place stated in the notice of convocation. The forms and timescale of the notice of convocation are governed by French laws.

Agenda

The notices and letters of call shall indicate the indications required by the law, particularly the agenda, the company electronic address where written questions of Shareholders may be sent and, eventually the mention of the obligation to collect the opinion or the prior approval of the mass of securities Shareholders giving access to the share capital.

The meeting may only deliberate on the matters placed on the agenda. It may, however, remove one or more directors at any time.

One or more shareholders representing the percentage of share capital required by law may, under the conditions and time limits set forth by law, require the inclusion on the agenda of draft resolutions.

In accordance to the Articles R 225 - 71 to R 225 - 74 of the Commercial Code, requests made by the Shareholders to register draft resolutions on the agenda and written questions are sent to the Headquarters by registered letter with recorded delivery beginning on the publication of the Meeting announcement and until 25 days before the General Meeting, or in a delay of 20 days beginning on the publication of the Meeting announcement, when this one is published more than 45 days before the General Meeting (date of reception of the request by the company will be taken into account).

The request of a new item on the agenda must be motivated. The request to register draft resolutions is provided with the text of draft resolutions, which may have a short explanation of reasons. These requests are subject to justification of possession or representation of required Share capital, in accordance to regulatory rules).

Moreover, in accordance to the Articles L. 2323 - 67 paragraph 2 of the Labor Code, requests of draft resolutions made by the Work Council, to be added on the agenda, are sent in the next 10 days following the publication of the Meeting announcement.

If the meeting has been unable to make a valid decision due to a lack of the required quorum, the second meeting and, where appropriate, the second meeting adjourned are called at least ten days in advance in the same form as the first meeting.

Admission to Meetings – Powers

Every shareholder has the right to attend General Meetings and to participate in the discussions, in person or by proxy, regardless of the number of shares held, on simple proof of identity and the ownership of shares. The right to participate in a General Meeting is subject to the condition that the shares must be recorded, in the name of the shareholder or the shareholder’s appointed broker, either in the nominative share accounts held by the company or in the bearer share accounts held by the authorized broker, by zero hours, Paris time, on the second working day prior to the meeting. The recording or registration of the shares in the bearer share accounts held by the authorized broker must be confirmed by a share certificate provided by the broker. This share certificate must be attached to the postal voting form, the proxy form or the application for an admission pass, issued in the name of the shareholder or on behalf of the shareholder represented by the appointed broker. A certificate must also be supplied to shareholders who wish to attend the General Meeting in person but who have not received an admission pass by zero hours, Paris time, on the second working day prior to the meeting.
A Shareholder may be represented by another Shareholder, his or her spouse or by the partner with who he or she signed a Civil Partnership. Furthermore, he or she may be represented by any other moral or physical person of his choice in accordance to the Articles L. 225-106 to -106-3 of the Commercial Code; in that aim, the representative must present valid proof of proxy.

The legal representatives of shareholders who are legally incapable or incapacitated and individuals representing corporate shareholders take part in meetings, whether or not they are shareholders. All Shareholders may also have a postal voting, using a registration form and sent to the company according to the law and regulations; to be acceptable this registration must be received by the company three days before the date of the Meeting.

In case of remote voting using an electronic vote, or a proxy vote given by electronic signature, this vote is made according to the conditions of the current regulations.

All legal documents relative to legal information for shareholders are made available to them at the registered office of the company.
Delegation granted for increase in capital by the Shareholders' meeting to the Board of Directors

### Delegation of competence

<table>
<thead>
<tr>
<th>Object - Duration</th>
<th>Limit</th>
<th>Use in 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ability to issue shares and/or securities giving access to the share capital of the company and/or securities giving the right to the allotment of the debt instruments, with preferential subscription rights of the shareholders.</td>
<td>The limit is €2,000,000 corresponding to the maximum nominal amount of the increase of the share capital and to the maximal nominal amount of the debt instruments and €500,000,000 on the maximum overall limit of the maximum nominal amount of the debt instruments.</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ability to issue shares and/or securities giving access to the share capital of the company and/or securities giving the right to the allotment of debt instruments, without preferential subscription rights of the shareholders - through public offerings.</td>
<td>The limit is deducted on the overall limit of €2,000,000 (increase of the share capital) and on the overall limit of €500,000,000 (debt instruments).</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ability to issue shares and/or securities giving access to the share capital of the Company and/or securities giving the right to the allotment of debt instruments, without preferential subscription rights of the shareholders - through private placements as set forth in article L.411-2 II of the French Monetary and Financial Code.</td>
<td>The limit is deducted on the overall limit of €2,000,000 (increase of the share capital) and on the overall limit of €500,000,000 (debt instruments).</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ability to increase the number of shares and/or securities giving access to the share capital of the Company to be issued in the event of a share capital increase with or without preferential subscription rights of the shareholders.</td>
<td>The limit amount 15% of initial issue of shares. It is deducted on the overall limit of €2,000,000 (increase of the share capital)</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ability to issue shares and/or securities giving access to the share capital of the Company, as consideration for securities tendered through public exchange offers initiated by the Company, without preferential subscription right of the shareholders.</td>
<td>The limit is deducted on the overall limit of €500,000,000 (increase of the share capital) and on the overall limit of €2,000,000,000 (debt instruments).</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ability to increase the share capital through the capitalization of reserves, earnings or premiums or any other sum upon which capitalization would be permitted.</td>
<td>The limit is €2,000,000 (corresponding to the maximum nominal amount of the increase of the share capital); It is a independent limit.</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ability to issue shares and/or securities giving access to the share capital giving the right to the allotment of debt instruments, without preferential subscription rights of the shareholders and reserved for members of saving plans.</td>
<td>The limit is €2,000,000 corresponding to the maximum nominal amount of the increase of the share capital; it is an independent limit.</td>
<td>None</td>
</tr>
<tr>
<td>Granted for a period of 26 months as from 03 April 2018</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Remuneration of the Members of the Board

The purpose of this report is to present a detailed explanation of the information mentioned in the Article L 225-37-3 I of the French commercial code concerning the remuneration due or awarded to the corporate officers for the 2019 financial year. This information will be subject to a resolution that will be proposed to the approval of the shareholders on March 24th, 2020.

In accordance with Article L225-37-2 of the French Commercial Code, the corporate officers' compensation policy, as described herein, will also be subject to a resolution to be proposed to the approval of the shareholders on March 24th, 2020.

Information about the Remuneration of the Directors who are members of the Executive Board of the major shareholder

The Executive Director, Joachim Kreuzburg, is at the same time Chairman of the Executive Board and René Fáber is member of the Executive Board of the major shareholder of Sartorius Stedim Biotech S.A. Both receive their fixed and variable remuneration from the major shareholder Sartorius AG. A portion of this remuneration is charged to Sartorius Stedim Biotech S.A., reflecting their roles as Executive Director and Director of the Company. A portion of both total remunerations is charged to the SSB Group for their management services based on their proportional work for Sartorius Stedim Biotech (please refer also to section "Related Parties" of the "Financial Statements and Notes"). This allocation key is applied to all components of their remuneration.

Remuneration of the Director who are chairman or member of the Executive Board of the major shareholder Sartorius AG (Joachim Kreuzburg, René Fáber)

General and Fixed Remuneration

The total amount of the remuneration of the chairman of the Executive Board of Sartorius AG, as well as for other members of this Executive Board, reflects the scope of the responsibilities of the member concerned, the member’s personal performance, the company’s economic situation and sustainable progress. In addition, this amount is benchmarked with those at peer companies and with the vertical remuneration structure within the company as well as at peer companies. Remuneration is comprised of both fixed non-performance-based components and of variable performance-based components, and is reviewed regularly to ensure that it remains appropriate. The variable performance-based remuneration components consist of those to be paid annually and of multi-year components intended to have a long-term incentive. Fixed non-performance-based remuneration is paid in the year in which it is granted. For 100% target achievement, the variable annual and long-term performance-based components generally represent at least half of total remuneration, which excludes pension commitments under a defined benefit plan as well as fringe benefits. The targets set for the performance-based remuneration refer to financial key figures of the Sartorius Group in which the Sartorius Stedim Biotech Group is fully consolidated. Specifically, Sartorius Stedim Biotech represents approx. 80% of the business and assets of the Sartorius Group. Therefore, the development of Sartorius Stedim Biotech has a significant influence on the financial results of the Sartorius Group and thus on the variable remuneration of Sartorius AG’s Executive Board members. However, all components of the remuneration described below refer to parameters and financial key figures of the Sartorius Group in total.

Variable Remuneration

The variable portion of this remuneration contains components that are paid annually (subordinate targets measured against sales revenue | order intake, underlying EBITDA and ratio of net debt to EBITDA) and components determined by multi-year assessment (measured against (i) consolidated net profit and (ii) the phantom stock plan).

The components to be annually paid and the elements determined by multi-year assessment each make up one half of the target achievement that is possible. A cap is provided for all variable components to be paid.
Of the total that can be awarded for 100% target achievement, the subordinate targets of the components to be annually paid are weighted within the components that are settled annually for the chairman of the Executive Board (Joachim Kreuzburg) as follows:

- sales revenue | order intake Group 30%;
- underlying EBITDA Group 40%;
- ratio of net debt to underlying EBITDA Group 30%.

Of the total that can be awarded for 100% target achievement, the subordinate targets of the components to be annually paid are weighted within the components that are settled annually for the member of the Executive Board responsible for the Bioprocess Solutions division (René Fáber) as follows:

- sales revenue | order intake Group 9%;
- underlying EBITDA Group 12%;
- ratio of net debt to underlying EBITDA Group 9%;
- sales revenue | order intake BPS division 30%;
- underlying EBITDA BPS division 40%;

The subordinate targets constituted by (i) consolidated net profit and (ii) the phantom stock plan as components determined by multi-year assessment are each weighted within the components with long-term incentive effect at 50%.

a) Annually paid variable remuneration

The portion of the variable remuneration that is to be paid annually depends on the degree to which the target is achieved, which the Supervisory Board of Sartorius AG defines by setting each individual subordinate target. Thus, target achievement is subdivided into the previously mentioned three subordinate targets, which are each separately paid.

Sales Revenue | Order Intake

If the degree of target achievement is below 90%, no remuneration is paid. If 90% is achieved, 50% of the sum awarded is paid out. Thereafter, payment increases linearly up to a target achievement of 104%, at which a maximum of 120% of the sum awarded is paid out. The degree of payment of 120% constitutes the cap for this subordinate target at the same time.

Underlying EBITDA

If the degree of target achievement is below 70%, no remuneration is paid. If 70% is achieved, 70% of the sum awarded is paid out. Thereafter, payment increases linearly up to a target achievement of 120%, at which a maximum of 120% of the sum awarded is paid out. The degree of payment of 120% constitutes the cap for this subordinate target at the same time.

Ratio of Net Debt to underlying EBITDA

No remuneration is paid if the ratio of net debt to underlying EBITDA achieved is below the lower limit defined. If this defined value is achieved, 50% of the sum awarded is paid out. Thereafter, payment increases linearly up to a target achievement of 120%, at which a maximum of 120% of the sum awarded is paid out. The degree of payment of 120% constitutes the cap for this subordinate target at the same time.

b) Variable remuneration with multi-year components

On the one hand, components determined by multi-year assessment depend on the degree to which the target is achieved, which the Supervisory Board of Sartorius AG defines by setting the subordinate target constituted by consolidated net profit. On the other hand, these multi-year components depend on the value of the monetary sum ascribed to the Executive Board member at the beginning of each year.
Consolidated Net Profit

For this subordinate target, the basis for assessment is the consolidated net profit after non-controlling interest excluding amortization (amortization of the value of intangible assets, such as customer databases or patents, which results from purchase price allocation within the scope of business combinations pursuant to IFRS 3). Target achievement for assessing annual variable remuneration is based on the average taken over a period of three fiscal years, beginning with the present fiscal year.

To smooth the amounts to be paid out, a partial payment amounting to 50% of the target achievement for a fiscal year will be effected. Any overpayments as a result of these partial payments will be offset in the following year against other remuneration components (fixed or variable). No partial payment will be made in the year prior to an Executive Board member's resignation. Full account is thus taken of any negative results, and the effects thereof continue to have an impact on the remuneration of the Executive Board member concerned even after he or she has left the company. If a defined minimum value is attained, payment of the awarded sum will increase linearly from 0% to a maximum of 120% of the subordinate target achievement value defined by the Supervisory Board. The degree of payment of 120% constitutes the cap for this subordinate target at the same time.

Phantom Stock Plan

Through the issue of shadow shares, called phantom stocks, the Executive Board members are treated as if they were owners of a certain number of shares in Sartorius AG, without, however, being entitled to receive dividends. The development of the value of these phantom stocks is linked with the development of the Sartorius share; both increases and decreases in the share price are taken into account. Later, this phantom stock is valued based on the share price at the time and its equivalent is paid out, provided that the associated conditions are met. Phantom stocks cannot be traded and does not entail any share subscription rights.

According to the Sartorius phantom stock plan, each Executive Board member is credited at the beginning of every year with phantom stock units valued at a agreed monetary sum. The value of these phantom stocks can be paid out only as an entire annual tranche. Payment can be requested, at the earliest, after a period of four years and no later than after eight years.

An Executive Board member is entitled to receive payment for phantom stock units only if the share price at the time of the payment request has appreciated at least 7.5% per year relative to the time the phantom stock was assigned or if the share price outperformed the TecDAX® as a comparative index. The phantom stock plan rules out subsequent changes to the parameters used for comparative stock valuation.

The amount to be paid is capped at a maximum of 2.5 times the share price at the time the phantom stocks were assigned, based in each case on the actual annual tranche concerned.

Assignment of this phantom stock and payment of its monetary equivalent depend on the mean value calculated from the average prices of the preference share in the closing auction of Xetra trading on the Frankfurt Stock Exchange over the last 20 days of trading of the previous year or over the last 20 days of trading prior to submission of the payment request. This serves to compensate for any short-term fluctuations in the share price.

Payment for phantom stocks is blocked for the four weeks preceding the scheduled publication date of quarterly and preliminary year-end results and for 20 days of trading on the stock exchange following the actual publication of quarterly and preliminary year-end results. These blackout periods are intended to prevent Executive Board members from profiting from potential insider knowledge.
Pension Commitments

According to the company’s remuneration policy, Executive Board members of Sartorius AG receive performance-related benefit commitments under a defined benefit plan when reappointed for the first time. In addition to including a basic pension, these commitments provide for the Executive Board member to make his own contribution from his variable earnings and for the company to match this contribution by a bonus amount. An Executive Board member may choose to receive such defined benefits in the form of a monthly retirement pension for old age or as a one-time payment to cover the member’s retirement pension for old age and invalidity as well as in the form of survivor’s benefits for the surviving spouse and children of the decedent.

Beyond such commitments, Joachim Kreuzburg is additionally entitled under a former company pension scheme to receive performance-based retirement benefits based on the salary of a German federal civil servant classified as grade 10 of salary class B for ministry officials according to the Federal Civil Service Remuneration Act [Bundesbesoldungsgesetz]. Such benefits are paid in the form of a retirement pension for old age and invalidity as well as in the form of survivors’ benefits for the surviving spouse and children of the decedent.

After a member has turned 65, this shall be considered the regular age limit at which this member shall automatically be entitled to receive all such benefits.

Other Remuneration Components

The remuneration system provides that the Supervisory Board of Sartorius AG at its discretion may grant an Executive Board member special compensation based on that member’s exceptional performance.

Severance Caps

The service contracts include a severance pay cap of a maximum of two annual salaries to cover cases in which Sartorius AG Executive Board membership is terminated prematurely. Potential amounts have to be paid by Sartorius AG.

Non-competition Clause

All Executive Board members of Sartorius AG have a post-contractual non-competition obligation, which is in accordance with German law. This obligation will last for two years after an Executive Board member has left the Group. During this time, if the non-competition clause is not waived or terminated, this Executive Board member may claim half of his most recent annual remuneration received from the company. Other income of the Executive Board member during this two year period is deducted from this payment. It should be noted that this payment is paid by Sartorius AG. However, an allocation of this payment would be recharged by Sartorius AG to Sartorius Stedim Biotech S.A. at the date of its payment.

Fringe Benefits

The members of the Executive Board of Sartorius AG are each entitled to use a company car, reclaim expenses incurred on business travel and to be covered by accident insurance and D&O insurance as fringe benefits in addition to receiving the remuneration components mentioned. The D&O insurance provides for the application of a deductible or excess in the amount required by law.

Share–based Payment

The remuneration policy for Executive Board members of Sartorius AG does not provide for the transfer of Sartorius AG shares as compensation for members. An exception to this was made in December 2014 and December 2019 for Joachim Kreuzburg in connection with his third and fourth appointment as a member of the Executive Board and its Chairman and CEO.

Consequently he holds now 100,000 shares of each class of shares out of his third appointment. The shares transferred are subject to a holding period that ended on November 10, 2019. The amount resulting since December 16, 2014, for the shares granted are to be spread as an employee benefits expense over the full vesting period and recognized as such in profit or loss. In fiscal 2019, an amount of €212 K (2018: €202 K) was accordingly recognized in the accounts of Sartorius Stedim Biotech.

The fourth term of Dr. Kreuzburg as a member and Chairman, as well as CEO, of the Executive Board of the company will expire on November 10, 2020. By resolution passed by the Supervisory Board on December 5, 2019, Dr. Kreuzburg was reappointed as a member and Chairman, as well as CEO, of the Executive Board of the company for the term from November 11, 2020, to November 10, 2025. Due to Dr. Kreuzburg’s special achievements in developing the Sartorius Group since the start of his tenure on the Executive Board on November 11, 2002, the company
wished to continue this successful collaboration with him. The new remuneration agreement therefore provides that 13,785 ordinary shares and 13,785 preference shares shall be transferred as a supplementary compensation component to Dr. Kreuzburg. This share-based payment is subject to the rules of IFRS 2 and is deemed to have been granted upon the resolution approved by the Supervisory Board on December 5, 2019. The following basic structure has been agreed upon: The transfer of the shares granted shall be effected at the time to be determined by Dr. Kreuzburg, but no earlier than on November 11, 2020. The shares granted shall be subject to a holding period that will end on November 10, 2024. Should Dr. Kreuzburg leave the company prior to November 11, 2022, at his own request, his entitlements to be granted said shares by transfer shall lapse in their entirety. If Dr. Kreuzburg leaves the company after November 11, 2022, and before November 11, 2024, at his own request, half of his entitlements to be granted said shares shall lapse. Shares already transferred and for which his entitlements have lapsed shall be returned to the company. This remuneration component is to be included in his total remuneration at fair value as of the grant date of these shares. This respective fair value is to be derived from the number of shares granted and the price of each class of share on the grant date and amounts to €5,000 K. Considering the conditions agreed, the amount resulting as of December 5, 2019, is to be spread as an employee benefits expense over the full vesting period of the plan and recognized as such in profit or loss. In fiscal 2019, an amount of €94 K was accordingly recognized as an employee benefits expense resulting from the grant of shares.

Information about the Remuneration of the Non-Executive Directors

The remuneration for non-executive board members is defined in the Board of Directors internal rules of Sartorius Stedim Biotech S.A. and comprises fixed remuneration, meeting Directors’ fees and reimbursement of out-of-pocket expenses. Members also serving as a member of a committee of the Board receive higher fixed remuneration.

| Joachim Kreuzburg (Chairman of the Board and Chief Executive Officer) |
| € in K | Year 2019 | Year 2018 |
| Remuneration due | 2,735 | 2,522 |
| Valuation of options granted during the reporting period | 0 | 0 |
| Valuation of the performance of shares granted in previous years | 0 | 0 |
| Total | 2,735 | 2,522 |

The amount cross-charged by the company Sartorius AG to the Sartorius Stedim Biotech Group concerning Joachim Kreuzburg is €1.166 K (2018: €1.348 K), the amount charged to Sartorius Stedim Biotech S.A. is submitted to the vote of the Annual Shareholders’ Meeting in accordance with the AFEP-MEDEF code and amounted to €583 K (2018: €674 K).

Pension Commitments

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Joachim Kreuzburg</td>
<td>252</td>
<td>4,416</td>
<td>3,385</td>
<td>270</td>
<td>257</td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>4,416</td>
<td>3,385</td>
<td>270</td>
<td>257</td>
</tr>
</tbody>
</table>
## Summary of the Remuneration for Each Executive Board Member

Joachim Kreuzburg⁵
(Chairman of the Board and Chief Executive Officer)

<table>
<thead>
<tr>
<th>€ in K</th>
<th>Year 2019</th>
<th>Year 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amounts due</td>
<td>Amounts paid</td>
</tr>
<tr>
<td>Fixed remuneration</td>
<td>888</td>
<td>888</td>
</tr>
<tr>
<td>Variable remuneration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annually paid</td>
<td>495</td>
<td>455</td>
</tr>
<tr>
<td>Long-term incentive</td>
<td>1,337</td>
<td>643</td>
</tr>
<tr>
<td>Exceptional remuneration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director’s fees</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benefits in kind⁰</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Total</td>
<td>2,735</td>
<td>2,001</td>
</tr>
</tbody>
</table>

1) Joachim Kreuzburg receives his salary from Sartorius AG for his duties performed for the entire Sartorius Group. His remuneration is determined annually by the Supervisory Board of Sartorius AG.

2) Company Car

## Table on Directors’ Meeting Fees and Other Remuneration Received by Non-executive Board Members

<table>
<thead>
<tr>
<th>€ in K</th>
<th>Year 2019</th>
<th>Year 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Director’s fees</td>
<td>Other remuneration</td>
</tr>
<tr>
<td>Liliane de Lassus</td>
<td>13.7</td>
<td>47.4</td>
</tr>
<tr>
<td>Bernard Lemaitre</td>
<td>13.7</td>
<td>47.4</td>
</tr>
<tr>
<td>Pascale Boissel</td>
<td>37.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Henri Riey</td>
<td>46.4</td>
<td>50.2</td>
</tr>
<tr>
<td>Susan Dexter</td>
<td>37.7</td>
<td>36.2</td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td>45.5</td>
<td>36.2</td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td>55.0</td>
<td>51.4</td>
</tr>
<tr>
<td>René Fäber⁵</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Total</td>
<td>249.3</td>
<td>268.8</td>
</tr>
</tbody>
</table>

1) René Fäber receives his salary from Sartorius AG for his duties performed for the entire Sartorius Group. His remuneration is determined annually by the Supervisory Board of Sartorius AG.
### Performance Shares Available for Each Board Member

Performance shares available for each corporate officer

<table>
<thead>
<tr>
<th>Performance shares available for each corporate officer</th>
<th>Date of the plan</th>
<th>Number of shares available during the reporting period</th>
<th>Acquisition conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joachim Kreuzburg</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>René Fáber</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Liliane de Lassus</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Bernard Lemaître</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Henri Riey</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Susan Dexter</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td></td>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) The performance shares are bonuses allocated to the Board members within the framework of the L225-197-1 articles and following of the commercial law, and which are subjected to additional requirements laid down by the recommendations AFEP/MEDEF of October 2008.

The performance shares are bonuses allocated pursuant to the provisions of Articles L225-197-1 and the following of French commercial law and according to the recommendations of the AFEP/MEDEF Code.

### Performance Shares Granted to Board Members

There is no performance share program in place for the board members of Sartorius Stedim Biotech S.A.

The information provided in the table below refers to the phantom stock plan of Sartorius AG. This plan only relates to Joachim Kreuzburg who is Chairman of the Executive Board of Sartorius AG.

<table>
<thead>
<tr>
<th>Performance shares granted by the AGM during the reporting period to any corporate officer by the issuer or any other company of the Group</th>
<th>Date of the plan</th>
<th>Number of shares granted during the year</th>
<th>Valuation of the shares according to the consolidated accounts methodology</th>
<th>Date of acquisition</th>
<th>Date of availability</th>
<th>Performance conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joachim Kreuzburg</td>
<td></td>
<td>1,950</td>
<td></td>
<td>Jan. 1, 2019</td>
<td>Jan. 1, 2023</td>
<td></td>
</tr>
<tr>
<td>René Fáber</td>
<td></td>
<td>934</td>
<td></td>
<td>Jan. 1, 2019</td>
<td>Jan. 1, 2023</td>
<td></td>
</tr>
<tr>
<td>Liliane de Lassus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bernard Lemaître</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henri Riey</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Dexter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>2,884</strong></td>
<td></td>
<td></td>
<td><strong>495</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of the plan</th>
<th>Number of shares granted during the year</th>
<th>Valuation of the shares according to the consolidated accounts methodology</th>
<th>Date of acquisition</th>
<th>Date of availability</th>
<th>Performance conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>€ in K</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,026</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phantom Stocks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>495</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sartorius AG shares granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>531</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Joachim Kreuzburg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>866</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phantom Stocks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>335</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sartorius AG shares granted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>531</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. René Fáber</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phantom Stocks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2019 € in K: 1,026; 2018 € in K: 743
### Corporate Governance

#### Remuneration of the Members of the Board

<table>
<thead>
<tr>
<th>Dr. Joachim Kreuzburg</th>
<th>Number of phantom stock units</th>
<th>Subscription price in €</th>
<th>Fair value when granted on Jan. 1 of the particular year € in K</th>
<th>Fair value at year-end on Dec. 31, 2018 € in K</th>
<th>Fair value at year-end on Dec. 31, 2019 € in K</th>
<th>Paid out € in K</th>
<th>Change in fair value in 2019</th>
<th>Exercisable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tranche of phantom stock units for 2015</td>
<td>7,360</td>
<td>24.70</td>
<td>182</td>
<td>454</td>
<td>0</td>
<td>454</td>
<td>paid in 2019</td>
<td>no</td>
</tr>
<tr>
<td>Tranche of phantom stock units for 2016</td>
<td>3,484</td>
<td>57.41</td>
<td>200</td>
<td>359</td>
<td>500</td>
<td>0</td>
<td>141</td>
<td>no</td>
</tr>
<tr>
<td>Tranche of phantom stock units for 2017</td>
<td>2,950</td>
<td>70.51</td>
<td>208</td>
<td>281</td>
<td>520</td>
<td>0</td>
<td>239</td>
<td>no</td>
</tr>
<tr>
<td>Tranche of phantom stock units for 2018</td>
<td>2,685</td>
<td>80.32</td>
<td>216</td>
<td>239</td>
<td>493</td>
<td>0</td>
<td>254</td>
<td>no</td>
</tr>
<tr>
<td><strong>Total tranches previous years</strong></td>
<td><strong>16,479</strong></td>
<td><strong>806</strong></td>
<td><strong>1,333</strong></td>
<td><strong>1,513</strong></td>
<td><strong>454</strong></td>
<td><strong>634</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tranche of phantom stock units for 2019</td>
<td>1,950</td>
<td>113.78</td>
<td>222</td>
<td>0</td>
<td>335</td>
<td>0</td>
<td>113</td>
<td>no</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>18,429</strong></td>
<td><strong>1,028</strong></td>
<td><strong>1,333</strong></td>
<td><strong>1,848</strong></td>
<td><strong>454</strong></td>
<td><strong>747</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dr. René Fáber</th>
<th>Number of phantom stock units</th>
<th>Subscription price in €</th>
<th>Fair value when granted on Jan. 1 of the particular year € in K</th>
<th>Fair value at year-end on Dec. 31, 2018 € in K</th>
<th>Fair value at year-end on Dec. 31, 2019 € in K</th>
<th>Paid out € in K</th>
<th>Change in fair value in 2019</th>
<th>Exercisable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tranche of phantom stock units for 2019</td>
<td>934</td>
<td>113.78</td>
<td>106</td>
<td>0</td>
<td>160</td>
<td>0</td>
<td>54</td>
<td>no</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>934</strong></td>
<td><strong>106</strong></td>
<td><strong>0</strong></td>
<td><strong>160</strong></td>
<td><strong>0</strong></td>
<td><strong>54</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Stock Options Granted During the Reporting Period to the Board Members by the Issuer or Any Other Company of the Group**

Not applicable

**Stock Options Granted during the Reporting Period by Each Board Member**

Not applicable

**Stock Options Exercised During the Reporting Period by Each Board Member**

Not applicable

---

**Additional Information about the Executive Board Members**

<table>
<thead>
<tr>
<th>Corporate officer</th>
<th>Employment contract</th>
<th>Additional pension plan</th>
<th>Indemnities or compensation due with regard to termination of contracts or positions</th>
<th>Non-competition clause indemnities</th>
</tr>
</thead>
</table>

---

[1] Joachim Kreuzburg has a service contract (without social security components) with Sartorius AG for their duties performed as members of the Executive Board of the major shareholder Sartorius AG. This is standard practice in Germany. The contracts include a cap regarding potential severance payments at the maximum of a two years annual remuneration. Furthermore there is a post-contractual non-competition clause obligation, that will last for two years after an Executive Board member has left the Group. During this time, if the non-competition clause is not waived or terminated, this Executive Board member may claim half of his most recent annual remuneration received from the company.

[2] Additionally there is a general pension plan in place at the Sartorius AG level for Joachim Kreuzburg. The level of the entitlement to benefits paid under this plan depends on his respective tenure.
Independent Auditors' Fees

Principal Independent Auditors

KPMG S.A.
480, avenue du Prado – CS 90021 – 13272 Marseille Cedex 08 – France
Represented by John Evans.
First commissioned by the Annual General Shareholders' Meeting on 7 April 2015.
Date commission expires: 2021 Annual General Shareholders' Meeting to approve the 2020 financial statements.
Member of the Compagnie régionale de Versailles.

Deloitte et Associés
7, boulevard Jacques Saadé - Quai de la Joliette – 13235 Marseille Cedex 2 – France
Represented by Philippe Battisti.
First commissioned by the Annual General Shareholders' Meeting on 19 May 2006.
Date commission expires: 2024 Annual General Shareholders' Meeting to approve the 2023 financial statements.
Member of the Compagnie régionale de Versailles.

Independent Auditors' Fees

<table>
<thead>
<tr>
<th></th>
<th>€ in K</th>
<th>KPMG 2018</th>
<th>2019</th>
<th>Deloitte 2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Audit</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Independent audit,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>certification,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>parent company &amp;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>consolidated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>financial statements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent company</td>
<td>63</td>
<td>8.3%</td>
<td>61</td>
<td>7.4%</td>
<td>55</td>
</tr>
<tr>
<td>Subsidiaries</td>
<td>799</td>
<td>90.4%</td>
<td>754</td>
<td>92.0%</td>
<td>94</td>
</tr>
<tr>
<td>Services directly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>related to audit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>services</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parent company</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsidiaries</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>862</td>
<td>98.6%</td>
<td>815</td>
<td>99.5%</td>
<td>149</td>
</tr>
<tr>
<td><strong>Other services</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legal, tax, corporate</td>
<td>12</td>
<td>1.4%</td>
<td>5</td>
<td>0.5%</td>
<td>0</td>
</tr>
<tr>
<td>Information technology, other</td>
<td>0</td>
<td>0.0%</td>
<td>0</td>
<td>0.0%</td>
<td>0</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>12</td>
<td>1.4%</td>
<td>5</td>
<td>0.5%</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>874</td>
<td>100.0%</td>
<td>820</td>
<td>100%</td>
<td>149</td>
</tr>
</tbody>
</table>
**Substitute Independent Auditors**

**SALUSTRO REYDEL**

Tour Eqho - 2 avenue Gambetta - 92066 Paris La Défense Cedex

First commissioned by the Annual General Shareholders’ Meeting on 7 April 2015.

Date commission expires: 2021 Annual General Shareholders’ Meeting to approve the 2020 financial statements.

Member of the Compagnie régionale de Versailles.

<table>
<thead>
<tr>
<th></th>
<th>Other 2019</th>
<th>Other 2018</th>
<th>Total 2019</th>
<th>Total 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>76</td>
<td>35.0%</td>
<td>60 37.8%</td>
<td>969 78.1%</td>
<td>905 80.6%</td>
</tr>
<tr>
<td>76</td>
<td>35.0%</td>
<td>60 37.8%</td>
<td>1,087 87.6%</td>
<td>1,020 90.8%</td>
</tr>
<tr>
<td>117</td>
<td>53.5%</td>
<td>51 32.4%</td>
<td>129 10.4%</td>
<td>56 5.0%</td>
</tr>
<tr>
<td>25</td>
<td>11.5%</td>
<td>47 29.7%</td>
<td>25 2.0%</td>
<td>47 4.2%</td>
</tr>
<tr>
<td>142</td>
<td>65.0%</td>
<td>98 62.2%</td>
<td>154 12.4%</td>
<td>103 9.2%</td>
</tr>
<tr>
<td>218</td>
<td>100.0%</td>
<td>158 100%</td>
<td>1,241 100.0%</td>
<td>1,123 100%</td>
</tr>
</tbody>
</table>
